$60 Million Later, Biotech Altea Therapeutics Calls it Quits
12/9/2011 8:16:02 AM
More...
|
Altea Therapeutics and KAI Pharmaceuticals, Inc. Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides
1/13/2010 9:32:04 AM
More...
|
Altea Therapeutics Announces Senior R&D Management Appointments to Align Product Development with Needs of Commercialization Partners
5/5/2009 9:40:39 AM
More...
|
Altea Therapeutics Announces Development and Commercialization Agreement with Amylin Pharmaceuticals, Inc. (AMLN) and Eli Lilly and Company (LLY) for an Investigational Transdermal Exenatide
4/1/2009 6:57:14 AM
More...
|
Altea Therapeutics Forms Premier Scientific Advisory Board
8/8/2008 8:31:48 AM
More...
|
Altea Therapeutics and Hospira, Inc. (HSP) Enter into Development and Commercialization Agreement for Transdermal Product; Altea Could Receive Milestone Payments up to $109M and Royalties
7/2/2008 6:36:42 AM
More...
|
Altea Therapeutics Appoints Dr. Richard H. Guy to its Scientific Advisory Board
2/13/2008 9:11:43 AM
More...
|
UCB Group (UCBJF.PK), Altea Therapeutics Leaders Elected Georgia Bio Co-Chairs for 2008
12/17/2007 10:32:50 AM
More...
|
Altea Therapeutics Achieves Successful Transdermal Delivery of Therapeutic Carbohydrate Macromolecules; Signs Research Agreement with Major Pharmaceutical Company
5/3/2007 1:46:50 PM
More...
|
Frost & Sullivan Commends Altea Therapeutics for Extending the Frontiers of Transdermal Drug Delivery
4/3/2007 12:38:01 PM
More...
|
|